I've honestly not heard of deferred accelerated approval. Had no luck digging anything up from FDA site. Have a link handy?
On the surface, the concept doesn't seem like it would fly in the marketplace if / when the phase III misses its survival endpoint. The drug would become iressa would it not? Being marketed with the spectre of a failed survival trial over its head. Thoughts?
Market Data 
Markets 
AI
